Featured Story

  • The synNotch solution: UCSF scientists engineer a next-gen T-cell immunotherapy

    CAR-T has been all the rage in cancer R&D for several years now as a slate of biotech upstarts pursue highly promising work reengineering T cells into attack weapons by adding a chimeric antigen receptor that can zero in on particular cancer cells. The approach has been highly effective in acute lymphoblastic leukemia, triggering an attack on B cells by homing in on the CD19 antigen, a breakthrough that has inspired a race to the regulatory finish line with the first CAR-Ts.

U.K. scientists get a green light to modify human embryos

Fertilization experts in the U.K. have been given a green light to start modifying human embryos, an experiment which they expect will give them unique insights into the way in which an embryo transforms into a healthy baby.

Gene therapy pioneer James Wilson uses CRISPR/Cas9 to target liver disease

One of the pioneers in the whole gene therapy movement of the past 35 years has combined his knowledge of viral vectors with the hot new CRISPR/Cas9 tech to tackle a rare genetic liver disease. And his work with rodents highlighted both the promise of this new technology as well as an unexpected hurdle.

Researchers discover fusion protein that promotes cancer via three distinct ways in pediatric brain tumors

Scientists at The Children's Hospital of Philadelphia (CHOP) and the Dana Farber Cancer Institute have uncovered an important cancer-driving fusion protein that promotes a pediatric brain tumor via three distinct mechanisms.

Investigators at The Hutch draw up a new battle plan for metastasis

Research coming from the Fred Hutchinson Cancer Research Center and Johns Hopkins Medical Institute concludes that the deadly spreading of cancer occurs in clusters rather than single cancer cells.

Boston Children's team finds potential new melanoma drug target using zebrafish

Why some cancer-prone cells don't ever cross the line into actually becoming malignant is a mystery that has long eluded scientists. Now, researchers at Boston Children's Hospital have answered that question, at least for melanoma. And in doing so, the team visualized for the first time the spread of cancer from a single cell and identified a set of genes as a potential new drug target.


From Our Sister Sites


The government of Japan is changing the lucrative brand-name healthcare market as its population ages and requires more drugs with a push to make at least 80% of the government's drug spending be for generics.


Tokyo-based Eisai said it will start selling active pharmaceutical ingredients to domestic generic makers and will invest "tens of millions of dollars" to scale up production at its India plant in Andhra Pradesh.